There was evidence that AI augmentation could be useful in low-volume centers lacking enough patients to maintain expertise.

When measured objectively, baseline adherence was “much, much worse” than expected in this first trial from the ESC.

LONDON, England—The new version of the European atrial fibrillation (AF) guidelines presents a pathway, called AF-CARE, to ...

The trial shows that a relaxed approach is no worse than proactively keeping serum levels in the high-normal range.

The definition of hypertension remains at an office BP ≥ 140/90 mm Hg but the guideline writers lowered the systolic ...

An early CV benefit was apparent, although there’s still some question about the longer-term impact versus culprit-only PCI.

A flurry of papers, including a meta-analysis of the three RCTs, reflect big interest and even larger, unanswered questions.

Quickly cutting non-HDL cholesterol after MI lowers the risk of MACE compared with stepwise use of lipid-lowering therapy.

This month’s greatest hits ran the gamut: a price drop for tirzepatide, TriClip’s US debut, advances in HF, and more.

Though there are limitations, the sham-controlled trial shows “no clinically relevant placebo effect,” a researcher says.

Discussion at ESC 2024 centered on questions of dosing, patients, and appropriate targets for this novel antithrombotic.

No impact was seen on mortality between the invasive and medical arms, but other endpoints may mean more to patients.